CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: Clinical Effectiveness and Guidelines

Last updated: April 6, 2018
Project Number: RB1206-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of therapeutic drug monitoring-guided dosing of biologic medications for patients with inflammatory bowel disease?
  2. What are the evidence-based guidelines regarding the use of therapeutic drug monitoring of biologic medication levels, and associated dosage adjustments, for patients with inflammatory bowel disease?

Key Message

One systematic review with meta-analysis, one randomized controlled trial, and two non-randomized studies were identified regarding the clinical effectiveness of therapeutic drug monitoring-guided dosing of biologic medications for patients with inflammatory bowel disease. Additionally, three evidence-based guidelines were identified.